Generative Artificial Intelligence and Large Language Models in Clinical Oncology

Abstract

Cancer remains a major global health challenge, and the increasing availability of multimodal biomedical data has created unprecedented opportunities for precision oncology. Recent advances in generative artificial intelligence (AI), particularly large language models (LLMs), have enabled new approaches for integrating heterogeneous data sources, including electronic health records, medical imaging, pathology, genomics, and clinical text. However, current studies remain fragmented across specific tasks, cancer types, and model architectures, and a comprehensive synthesis of how generative AI can support the entire oncology continuum is still lacking. This review provides an overview of generative AI in clinical oncology, covering LLMs, generative adversarial networks, diffusion models, and multimodal foundation models. We summarize their methodological foundations and discuss applications in cancer diagnosis, prognosis prediction, treatment planning, patient management, and clinical trial optimization. Particular attention is given to multimodal data integration, synthetic data generation, clinical reasoning, and decision support, together with current challenges related to interpretability, reliability, data privacy, regulatory governance, and real-world implementation. By consolidating recent technological advances and clinical evidence, this review highlights future priorities toward safe, trustworthy, and clinically deployable intelligent oncology systems. Emerging agent-based architectures and human–AI collaborative workflows may further expand the clinical utility of generative AI in oncology.

Keywords

clinical decision support / generative artificial intelligence / large language models / multimodal data integration / oncology

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74 (2024): 12–49.

[2] J. Qi, M. Li, L. Wang, et al., “National and Subnational Trends in Cancer Burden in China, 2005–20: An Analysis of National Mortality Surveillance Data,” The Lancet Public Health 8 (2023): e943–e955.

[3] J. Kim, A. Harper, V. McCormack, et al., “Global Patterns and Trends in Breast Cancer Incidence and Mortality Across 185 Countries,” Nature Medicine 31 (2025): 1154–1162.

[4] X. Diao, C. Guo, Y. Jin, et al., “Cancer Situation in China: An Analysis Based on the Global Epidemiological Data Released in 2024,” Cancer Communications (London, England) 45 (2025): 178–197.

[5] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74 (2024): 229–263.

[6] A. Wahida, L. Buschhorn, S. Fröhling, et al., “The Coming Decade in Precision Oncology: Six Riddles,” Nature Reviews Cancer 23 (2023): 43–54.

[7] K. M. Mendez, S. N. Reinke, R. S. Kelly, et al., “A Roadmap to Precision Medicine Through Post-genomic Electronic Medical Records,” Nature Communications 16 (2025): 1700.

[8] X. He, X. Liu, F. Zuo, H. Shi, and J. Jing, “Artificial Intelligence-Based Multi-Omics Analysis Fuels Cancer Precision Medicine,” Seminars in Cancer Biology 88 (2023): 187–200.

[9] H. Wang, T. Fu, Y. Du, et al., “Scientific Discovery in the Age of Artificial Intelligence,” Nature 620 (2023): 47–60.

[10] J. He, S. L. Baxter, J. Xu, J. Xu, X. Zhou, and K. Zhang, “The Practical Implementation of Artificial Intelligence Technologies in Medicine,” Nature Medicine 25 (2019): 30–36.

[11] A. Shmatko, N. Ghaffari Laleh, M. Gerstung, and J. N. Kather, “Artificial Intelligence in Histopathology: Enhancing Cancer Research and Clinical Oncology,” Nature Cancer 3 (2022): 1026–1038.

[12] E. Fountzilas, T. Pearce, M. A. Baysal, A. Chakraborty, and A. M. Tsimberidou, “Convergence of Evolving Artificial Intelligence and Machine Learning Techniques in Precision Oncology,” NPJ Digital Medicine 8 (2025): 75.

[13] S. Bedi, Y. Liu, L. Orr-Ewing, et al., “Testing and Evaluation of Health Care Applications of Large Language Models: A Systematic Review,” Jama 333 (2025): 319–328.

[14] J. Lipkova, R. J. Chen, B. Chen, et al., “Artificial Intelligence for Multimodal Data Integration in Oncology,” Cancer Cell 40 (2022): 1095–1110.

[15] B. Gomes and E. A. Ashley, “Artificial Intelligence in Molecular Medicine,” The New England Journal of Medicine 388 (2023): 2456–2465.

[16] L. Wu, J. Zhuang, Y. Zhou, et al., “Large-Scale Generative Tumor Synthesis in Computed Tomography Images for Improving Tumor Recognition,” Nature Communications 16 (2025): 11053.

[17] S. Kumar, T. R. Sumers, T. Yamakoshi, et al., “Shared Functional Specialization in Transformer-Based Language Models and the human Brain,” Nature Communications 15 (2024): 5523.

[18] A. Esteva, A. Robicquet, B. Ramsundar, et al., “A Guide to Deep Learning in Healthcare,” Nature Medicine 25 (2019): 24–29.

[19] T. Tu, M. Schaekermann, A. Palepu, et al., “Towards Conversational Diagnostic Artificial Intelligence,” Nature 642 (2025): 442–450.

[20] D. McDuff, M. Schaekermann, T. Tu, et al., “Towards Accurate Differential Diagnosis With Large Language Models,” Nature 642 (2025): 451–457.

[21] P. Qiu, C. Wu, X. Zhang, et al., “Towards Building Multilingual Language Model for Medicine,” Nature Communications 15 (2024): 8384.

[22] V. M. Rao, M. Hla, M. Moor, et al., “Multimodal Generative AI for Medical Image Interpretation,” Nature 639 (2025): 888–896.

[23] K. Singhal, T. Tu, J. Gottweis, et al., “Toward Expert-level Medical Question Answering With Large Language Models,” Nature Medicine 31 (2025): 943–950.

[24] Medical Large Language Model for Diagnostic Reasoning Across Specialties, Nature Medicine 31 (2025): 743–744.

[25] A. M. Conard, M. Hughes, J. Hall, et al., “Tackling the Complexity of Cancer With Generative Models,” Cell 189 (2026): 2218–2231.

[26] K. Singhal, S. Azizi, T. Tu, et al., “Large Language Models Encode Clinical Knowledge,” Nature 620 (2023): 172–180.

[27] M. Moor, O. Banerjee, Z. S. H. Abad, et al., “Foundation Models for Generalist Medical Artificial Intelligence,” Nature 616 (2023): 259–265.

[28] S. Noy and W. Zhang, “Experimental Evidence on the Productivity Effects of Generative Artificial Intelligence,” Science (New York, NY) 381 (2023): 187–192.

[29] M. Fernández-Pichel, J. C. Pichel, and D. E. Losada, “Evaluating Search Engines and Large Language Models for Answering Health Questions,” NPJ Digital Medicine 8 (2025): 153.

[30] S. Johri, J. Jeong, B. A. Tran, et al., “An Evaluation Framework for Clinical Use of Large Language Models in Patient Interaction Tasks,” Nature Medicine 31 (2025): 77–86.

[31] P. Wan, Z. Huang, W. Tang, et al., “Outpatient Reception via Collaboration Between Nurses and a Large Language Model: A Randomized Controlled Trial,” Nature Medicine 30 (2024): 2878–2885.

[32] D. Van Veen, C. Van Uden, L. Blankemeier, et al., “Adapted Large Language Models Can Outperform Medical Experts in Clinical Text Summarization,” Nature Medicine 30 (2024): 1134–1142.

[33] C. Alba, B. Xue, J. Abraham, T. Kannampallil, and C. Lu, “The Foundational Capabilities of Large Language Models in Predicting Postoperative Risks Using Clinical Notes,” NPJ Digital Medicine 8 (2025): 95.

[34] F. Liu, H. Zhou, K. Wang, et al., “MetaGP: A Generative Foundation Model Integrating Electronic Health Records and Multimodal Imaging for Addressing Unmet Clinical Needs,” Cell Reports Medicine 6 (2025): 102056.

[35] Reflections on DeepSeek's Breakthrough, National science review 12 (2025): nwaf044.

[36] F. Liu, T. Zhu, X. Wu, et al., “A Medical Multimodal Large Language Model for Future Pandemics,” NPJ Digital Medicine 6 (2023): 226.

[37] W. Lotter, M. J. Hassett, N. Schultz, K. L. Kehl, E. M. Van Allen, and E. Cerami, “Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions,” Cancer Discovery 14 (2024): 711–726.

[38] T. G. Chang, S. Park, A. A. Schäffer, P. Jiang, and E. Ruppin, “Hallmarks of Artificial Intelligence Contributions to Precision Oncology,” Nature Cancer 6 (2025): 417–431.

[39] S. Tan, X. Xin, and D. Wu, “ChatGPT in Medicine: Prospects and Challenges: A Review Article,” International Journal of Surgery (London, England) 110 (2024): 3701–3706.

[40] E. Goh, R. J. Gallo, E. Strong, et al., “GPT-4 Assistance for Improvement of Physician Performance on Patient Care Tasks: A Randomized Controlled Trial,” Nature Medicine 31 (2025): 1233–1238.

[41] S. Sandmann, S. Riepenhausen, L. Plagwitz, and J. Varghese, “Systematic Analysis of ChatGPT, Google Search and Llama 2 for Clinical Decision Support Tasks,” Nature Communications 15 (2024): 2050.

[42] Q. Chen, Y. Hu, X. Peng, et al., “Benchmarking Large Language Models for Biomedical Natural Language Processing Applications and Recommendations,” Nature Communications 16 (2025): 3280.

[43] S. Sandmann, S. Hegselmann, M. Fujarski, et al., “Benchmark Evaluation of DeepSeek Large Language Models in Clinical Decision-making,” Nature Medicine 31 (2025): 2546–2549.

[44] M. Tordjman, Z. Liu, M. Yuce, et al., “Comparative Benchmarking of the DeepSeek Large Language Model on Medical Tasks and Clinical Reasoning,” Nature Medicine 31 (2025): 2550–2555.

[45] C. Chen, J. Yu, Z. Xu, et al., “Pseudo-Contrast-enhanced US via Enhanced Generative Adversarial Networks for Evaluating Tumor Ablation Efficacy,” Radiology Artificial Intelligence 7 (2025): e240370.

[46] M. Zhu, Q. Yang, Z. Gao, Y. Yuan, and J. Liu, “FedBM: Stealing Knowledge From Pre-trained Language Models for Heterogeneous Federated Learning,” Medical Image Analysis 102 (2025): 103524.

[47] Y. Zheng, H. Y. Koh, J. Ju, et al., “Large Language Models for Scientific Discovery in Molecular Property Prediction,” Nature Machine Intelligence 7 (2025): 437–447.

[48] F. Dennstädt, J. Hastings, P. M. Putora, M. Schmerder, and N. Cihoric, “Implementing Large Language Models in Healthcare While Balancing Control, Collaboration, Costs and Security,” NPJ Digital Medicine 8 (2025): 143.

[49] X. Chen, H. Yi, M. You, et al., “Enhancing Diagnostic Capability With Multi-agents Conversational Large Language Models,” NPJ Digital Medicine 8 (2025): 159.

[50] R. Shusterman, A. C. Waters, S. O'Neill, M. Bangs, P. Luu, and D. M. Tucker, “An Active Inference Strategy for Prompting Reliable Responses From Large Language Models in Medical Practice,” NPJ Digital Medicine 8 (2025): 119.

[51] X. Liu, H. Liu, G. Yang, et al., “A Generalist Medical Language Model for Disease Diagnosis Assistance,” Nature Medicine 31 (2025): 932–942.

[52] J. Zhou, X. He, L. Sun, et al., “Pre-trained Multimodal Large Language Model Enhances Dermatological Diagnosis Using SkinGPT-4,” Nature Communications 15 (2024): 5649.

[53] Z. Huang, F. Bianchi, M. Yuksekgonul, T. J. Montine, and J. Zou, “A Visual-language Foundation Model for Pathology Image Analysis Using Medical Twitter,” Nature Medicine 29 (2023): 2307–2316.

[54] J. Jee, C. Fong, K. Pichotta, et al., “Automated Real-world Data Integration Improves Cancer Outcome Prediction,” Nature 636 (2024): 728–736.

[55] X. Wu, W. Li, and H. Tu, “Big Data and Artificial Intelligence in Cancer Research,” Trends in Cancer 10 (2024): 147–160.

[56] H. Xiang, Y. Xiao, F. Li, et al., “Development and Validation of an Interpretable Model Integrating Multimodal Information for Improving Ovarian Cancer Diagnosis,” Nature Communications 15 (2024): 2681.

[57] Z. Chen, Y. Chen, Y. Sun, et al., “Predicting Gastric Cancer Response to Anti-HER2 Therapy or Anti-HER2 Combined Immunotherapy Based on Multi-modal Data,” Signal Transduction and Targeted Therapy 9 (2024): 222.

[58] J. Xiang, X. Wang, X. Zhang, et al., “A Vision-language Foundation Model for Precision Oncology,” Nature 638 (2025): 769–778.

[59] J. Liu, X. Cen, C. Yi, et al., “Challenges in AI-driven Biomedical Multimodal Data Fusion and Analysis,” Genomics, Proteomics & Bioinformatics 23, no. 1 (2025):qzaf011.

[60] Z. Li, Y. Jiang, M. Lu, R. Li, and Y. Xia, “Survival Prediction via Hierarchical Multimodal Co-Attention Transformer: A Computational Histology-Radiology Solution,” IEEE Transactions on Medical Imaging 42 (2023): 2678–2689.

[61] Y. Mao, N. Xu, Y. Wu, et al., “Assessments of Lung Nodules by an Artificial Intelligence Chatbot Using Longitudinal CT Images,” Cell Reports Medicine 6 (2025): 101988.

[62] R. Tanno, D. G. T. Barrett, A. Sellergren, et al., “Collaboration Between Clinicians and Vision-language Models in Radiology Report Generation,” Nature Medicine 31 (2025): 599–608.

[63] F. M. Howard, H. M. Hieromnimon, S. Ramesh, et al., “Generative Adversarial Networks Accurately Reconstruct Pan-cancer Histology From Pathologic, Genomic, and Radiographic Latent Features,” Science Advances 10 (2024): eadq0856.

[64] R. Bhayana, B. Nanda, T. Dehkharghanian, et al., “Large Language Models for Automated Synoptic Reports and Resectability Categorization in Pancreatic Cancer,” Radiology 311 (2024): e233117.

[65] N. Tavakoli and D. Kim, “AI-generated Clinical Histories for Radiology Reports: Closing the Information Gap,” Radiology 314 (2025): e243910.

[66] E. Goh, R. Gallo, J. Hom, et al., “Large Language Model Influence on Diagnostic Reasoning: A Randomized Clinical Trial,” JAMA Network Open 7 (2024): e2440969.

[67] A. Saha, J. S. Bosma, J. J. Twilt, et al., “Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study,” The Lancet Oncology 25 (2024): 879–887.

[68] K. R. Laukamp, R. A. Terzis, J. M. Werner, et al., “Monitoring Patients With Glioblastoma by Using a Large Language Model: Accurate Summarization of Radiology Reports With GPT-4,” Radiology 312 (2024): e232640.

[69] L. Zhang, M. Liu, L. Wang, et al., “Constructing a Large Language Model to Generate Impressions From Findings in Radiology Reports,” Radiology 312 (2024): e240885.

[70] Z. Gao, G. Zhang, H. Liang, et al., “A Lung CT Vision Foundation Model Facilitating Disease Diagnosis and Medical Imaging,” Nature Communications 17 (2025): 35.

[71] H. Yu, Y. Li, N. Zhang, et al., “A Foundation Generative Model for Breast Ultrasound Image Analysis,” Nature Biomedical Engineering (2026): 1–13.

[72] J. Wang, K. Wang, Y. Yu, et al., “Self-improving Generative Foundation Model for Synthetic Medical Image Generation and Clinical Applications,” Nature Medicine 31 (2025): 609–617.

[73] G. Müller-Franzes, L. Huck, S. Tayebi Arasteh, et al., “Using Machine Learning to Reduce the Need for Contrast Agents in Breast MRI Through Synthetic Images,” Radiology 307 (2023): e222211.

[74] A. Kondepudi, M. Pekmezci, X. Hou, et al., “Foundation Models for Fast, Label-free Detection of Glioma Infiltration,” Nature 637 (2025): 439–445.

[75] H. Xu, N. Usuyama, J. Bagga, et al., “A Whole-slide Foundation Model for Digital Pathology From Real-world Data,” Nature 630 (2024): 181–188.

[76] E. Vorontsov, A. Bozkurt, A. Casson, et al., “A Foundation Model for Clinical-grade Computational Pathology and Rare Cancers Detection,” Nature Medicine 30 (2024): 2924–2935.

[77] X. Wang, J. Zhao, E. Marostica, et al., “A Pathology Foundation Model for Cancer Diagnosis and Prognosis Prediction,” Nature 634 (2024): 970–978.

[78] Z. Li, T. Su, B. Zhang, et al., “His-MMDM: Multi-Domain and Multi-Omics Translation of Histopathological Images With Diffusion Models,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 13 (2026): e18066.

[79] S. Dey, C. R. S. Banerji, P. Basuchowdhuri, S. K. Saha, D. Parashar, and T. Chakraborti, “Generating Crossmodal Gene Expression From Cancer Histopathology Improves Multimodal AI Predictions,” Nature Communications 17 (2025): 259.

[80] X. Qian, J. Pei, C. Han, et al., “A Multimodal Machine Learning Model for the Stratification of Breast Cancer Risk,” Nature Biomedical Engineering 9 (2025): 356–370.

[81] V. Hernström, V. Josefsson, H. Sartor, et al., “Screening Performance and Characteristics of Breast Cancer Detected in the Mammography Screening With Artificial Intelligence Trial (MASAI): A Randomised, Controlled, Parallel-group, Non-inferiority, Single-blinded, Screening Accuracy Study,” The Lancet Digital Health 7 (2025): e175–e183.

[82] M. Salim, Y. Liu, M. Sorkhei, et al., “AI-Based Selection of Individuals for Supplemental MRI in Population-Based Breast Cancer Screening: The Randomized ScreenTrustMRI Trial,” Nature Medicine 30 (2024): 2623–2630.

[83] T. Zhang, T. Tan, X. Wang, et al., “RadioLOGIC, a Healthcare Model for Processing Electronic Health Records and Decision-making in Breast Disease,” Cell Reports Medicine 4 (2023): 101131.

[84] C. Niu, Q. Lyu, C. D. Carothers, et al., “Medical Multimodal Multitask Foundation Model for Lung Cancer Screening,” Nature Communications 16 (2025): 1523.

[85] T. J. Loftus, A. Haider, and G. R. Upchurch Jr., “Practical Guide to Artificial Intelligence, Chatbots, and Large Language Models in Conducting and Reporting Research,” JAMA Surgery 160 (2025): 588–589.

[86] V. Berisha and J. M. Liss, “Responsible Development of Clinical Speech AI: Bridging the Gap Between Clinical Research and Technology,” NPJ Digital Medicine 7 (2024): 208.

[87] B. Gu, R. J. Desai, K. J. Lin, and J. Yang, “Probabilistic Medical Predictions of Large Language Models,” NPJ Digital Medicine 7 (2024): 367.

[88] Y. Sun, W. Tan, Z. Gu, et al., “A Data-efficient Strategy for Building High-performing Medical Foundation Models,” Nature Biomedical Engineering 9 (2025): 539–551.

[89] F. Liu, Z. Li, Q. Yin, et al., “A Multimodal Multidomain Multilingual Medical Foundation Model for Zero Shot Clinical Diagnosis,” NPJ Digital Medicine 8 (2025): 86.

[90] W. Huang, C. Li, H. Yang, et al., “Enhancing the Vision-language Foundation Model With Key Semantic Knowledge-emphasized Report Refinement,” Medical Image Analysis 97 (2024): 103299.

[91] K. Zhang, R. Zhou, E. Adhikarla, et al., “A Generalist Vision-language Foundation Model for Diverse Biomedical Tasks,” Nature Medicine 30 (2024): 3129–3141.

[92] S. Andani, B. Chen, J. Ficek-Pascual, et al., “Histopathology-Based Protein Multiplex Generation Using Deep Learning,” Nature Machine Intelligence 7 (2025): 1292–1307.

[93] L. Rasmy, Y. Xiang, Z. Xie, C. Tao, and D. Zhi, “Med-BERT: Pretrained Contextualized Embeddings on Large-Scale Structured Electronic Health Records for Disease Prediction,” NPJ Digital Medicine 4 (2021): 86.

[94] D. Ferber, G. Wölflein, I. C. Wiest, et al., “In-context Learning Enables Multimodal Large Language Models to Classify Cancer Pathology Images,” Nature Communications 15 (2024): 10104.

[95] R. J. Chen, M. Y. Lu, D. F. K. Williamson, et al., “Pan-cancer Integrative Histology-genomic Analysis via Multimodal Deep Learning,” Cancer Cell 40 (2022): 865–878.

[96] D. S. Bitterman, A. Downing, J. Maués, and M. Lustberg, “Promise and Perils of Large Language Models for Cancer Survivorship and Supportive Care,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 42 (2024): 1607–1611.

[97] G. K. Savova, I. Danciu, F. Alamudun, et al., “Use of Natural Language Processing to Extract Clinical Cancer Phenotypes From Electronic Medical Records,” Cancer Research 79 (2019): 5463–5470.

[98] K. L. Kehl, H. Elmarakeby, M. Nishino, et al., “Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes from Radiology Reports,” JAMA Oncology 5 (2019): 1421–1429.

[99] J. J. Nunez, B. Leung, C. Ho, A. T. Bates, and R. T. Ng, “Predicting the Survival of Patients with Cancer from Their Initial Oncology Consultation Document Using Natural Language Processing,” JAMA Network Open 6 (2023): e230813.

[100] K. L. Kehl, J. Jee, K. Pichotta, et al., “Shareable Artificial Intelligence to Extract Cancer Outcomes From Electronic Health Records for Precision Oncology Research,” Nature Communications 15 (2024): 9787.

[101] K. L. Kehl, W. Xu, A. Gusev, et al., “Artificial Intelligence-aided Clinical Annotation of a Large Multi-cancer Genomic Dataset,” Nature Communications 12 (2021): 7304.

[102] F. A. Wang, Z. Zhuang, F. Gao, et al., “TMO-Net: An Explainable Pretrained Multi-Omics Model for Multi-task Learning in Oncology,” Genome Biology 25 (2024): 149.

[103] G. K. Savova, E. Tseytlin, S. Finan, et al., “DeepPhe: A Natural Language Processing System for Extracting Cancer Phenotypes From Clinical Records,” Cancer Research 77 (2017): e115–e118.

[104] I. C. Wiest, D. Ferber, J. Zhu, et al., “Privacy-preserving Large Language Models for Structured Medical Information Retrieval,” NPJ Digital Medicine 7 (2024): 257.

[105] J. Jonnagaddala and Z. S. Wong, “Privacy Preserving Strategies for Electronic Health Records in the Era of Large Language Models,” NPJ Digital Medicine 8 (2025): 34.

[106] L. Peng, G. Luo, S. Zhou, et al., “An in-depth Evaluation of Federated Learning on Biomedical Natural Language Processing for Information Extraction,” NPJ Digital Medicine 7 (2024): 127.

[107] H. Chen, T. Zhu, W. Zhou, and W. Zhao, “AFed: Algorithmic Fair Federated Learning,” IEEE Transactions on Neural Networks and Learning Systems 36 (2025): 14764–14776.

[108] T. Savage, A. Nayak, R. Gallo, E. Rangan, and J. H. Chen, “Diagnostic Reasoning Prompts Reveal the Potential for Large Language Model Interpretability in Medicine,” NPJ Digital Medicine 7 (2024): 20.

[109] Z. Zhang, T. Luo, M. Yan, et al., “Voxel-level Radiomics and Deep Learning for Predicting Pathologic Complete Response in Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunotherapy and Chemotherapy,” Journal for Immunotherapy of Cancer 13, no. 3 (2025): e011149.

[110] J. Keyl, P. Keyl, G. Montavon, et al., “Decoding Pan-cancer Treatment Outcomes Using Multimodal Real-world Data and Explainable Artificial Intelligence,” Nature Cancer 6 (2025): 307–322.

[111] F. Gao, J. Ding, B. Gai, et al., “Interpretable Multimodal Fusion Model for Bridged Histology and Genomics Survival Prediction in Pan-Cancer,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12 (2025): e2407060.

[112] J. Li, J. Zhou, H. Wang, et al., “Trends in Disparities and Transitions of Treatment in Patients with Early Breast Cancer in China and the US, 2011 to 2021,” JAMA Network Open 6 (2023): e2321388.

[113] G. Zhang, Q. Jin, Y. Zhou, et al., “Closing the Gap Between Open Source and Commercial Large Language Models for Medical Evidence Summarization,” NPJ Digital Medicine 7 (2024): 239.

[114] S. Park, G. Kim, Y. Oh, et al., “Self-evolving Vision Transformer for Chest X-ray Diagnosis Through Knowledge Distillation,” Nature Communications 13 (2022): 3848.

[115] J. Shao, F. Wu, and J. Zhang, “Selective Knowledge Sharing for Privacy-preserving Federated Distillation Without a Good Teacher,” Nature Communications 15 (2024): 349.

[116] V. Sorin, E. Klang, M. Sklair-Levy, et al., “Large Language Model (ChatGPT) as a Support Tool for Breast Tumor Board,” NPJ Breast Cancer 9 (2023): 44.

[117] L. Deng, T. Wang, Z. Z. Yangzhang, et al., “Evaluation of Large Language Models in Breast Cancer Clinical Scenarios: A Comparative Analysis Based on ChatGPT-3.5, ChatGPT-4.0, and Claude2,” International Journal of Surgery (London, England) 110 (2024): 1941–1950.

[118] G. Arango-Argoty, E. Kipkogei, R. Stewart, et al., “Pretrained Transformers Applied to Clinical Studies Improve Predictions of Treatment Efficacy and Associated Biomarkers,” Nature Communications 16 (2025): 2101.

[119] W. Liu, J. Li, Y. Tang, et al., “DrBioRight 2.0: An LLM-powered Bioinformatics Chatbot for Large-Scale Cancer Functional Proteomics Analysis,” Nature Communications 16 (2025): 2256.

[120] Y. Oh, S. Park, H. K. Byun, et al., “LLM-driven Multimodal Target Volume Contouring in Radiation Oncology,” Nature Communications 15 (2024): 9186.

[121] C. Bluethgen, P. Chambon, J. B. Delbrouck, et al., “A Vision-language Foundation Model for the Generation of Realistic Chest X-ray Images,” Nature Biomedical Engineering 9 (2025): 494–506.

[122] C. Y. Li, K. J. Chang, C. F. Yang, et al., “Towards a Holistic Framework for Multimodal LLM in 3D Brain CT Radiology Report Generation,” Nature Communications 16 (2025): 2258.

[123] Z. Bai, M. Osman, M. Brendel, et al., “Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer via Interpretable Multimodal Deep Learning,” NPJ Digital Medicine 8 (2025): 174.

[124] T. Li, S. Shetty, A. Kamath, et al., “CancerGPT for Few Shot Drug Pair Synergy Prediction Using Large Pretrained Language Models,” NPJ Digital Medicine 7 (2024): 40.

[125] B. Feng, Z. Liu, N. Huang, et al., “A Bioactivity Foundation Model Using Pairwise Meta-learning,” Nature Machine Intelligence 6 (2024): 962–974.

[126] F. Carli, P. Di Chiaro, M. Morelli, et al., “Learning and Actioning General Principles of Cancer Cell Drug Sensitivity,” Nature Communications 16 (2025): 1654.

[127] Y. Feng, L. Zhou, C. Ma, Y. Zheng, R. He, and Y. Li, “Knowledge Graph-Based Thought: A Knowledge Graph-enhanced LLM Framework for Pan-cancer Question Answering,” GigaScience 14 (2025): giae082.

[128] S. Zhou, X. Luo, C. Chen, et al., “The Performance of Large Language Model-powered Chatbots Compared to Oncology Physicians on Colorectal Cancer Queries,” International Journal of Surgery (London, England) 110 (2024): 6509–6517.

[129] Y. Cao, H. Zhao, Y. Cheng, et al., “Survey on Large Language Model-Enhanced Reinforcement Learning: Concept, Taxonomy, and Methods,” IEEE Transactions on Neural Networks and Learning Systems 36 (2025): 9737–9757.

[130] S. Yin, C. Fu, S. Zhao, et al., “A Survey on Multimodal Large Language Models,” National Science Review 11 (2024): nwae403.

[131] A. Yalamanchili, B. Sengupta, J. Song, et al., “Quality of Large Language Model Responses to Radiation Oncology Patient Care Questions,” JAMA Network Open 7 (2024): e244630.

[132] A. Pan, D. Musheyev, D. Bockelman, S. Loeb, and A. E. Kabarriti, “Assessment of Artificial Intelligence Chatbot Responses to Top Searched Queries about Cancer,” JAMA Oncology 9 (2023): 1437–1440.

[133] A. J. Butte, “Artificial Intelligence-From Starting Pilots to Scalable Privilege,” JAMA Oncology 9 (2023): 1341–1342.

[134] S. Chen, B. H. Kann, M. B. Foote, et al., “Use of Artificial Intelligence Chatbots for Cancer Treatment Information,” JAMA Oncology 9 (2023): 1459–1462.

[135] Y. Zhang, X. Sui, F. Pan, et al., “A Comprehensive Large-Scale Biomedical Knowledge Graph for AI-powered Data-driven Biomedical Research,” Nature Machine Intelligence 7 (2025): 602–614.

[136] F. Di Martino and F. Delmastro, “Explainable AI for Clinical and Remote Health Applications: A Survey on Tabular and Time Series Data,” Artificial Intelligence Review 56 (2023): 5261–5315.

[137] T. Chanda, K. Hauser, S. Hobelsberger, et al., “Dermatologist-Like Explainable AI Enhances Trust and Confidence in Diagnosing Melanoma,” Nature Communications 15 (2024): 524.

[138] S. Kundu, “AI in Medicine Must be Explainable,” Nature Medicine 27 (2021): 1328.

[139] A. Yala, P. G. Mikhael, F. Strand, et al., “Toward Robust Mammography-Based Models for Breast Cancer Risk,” Science Translational Medicine 13, no. 578 (2021): eaba4373.

[140] N. Eisemann, S. Bunk, T. Mukama, et al., “Nationwide Real-world Implementation of AI for Cancer Detection in Population-Based Mammography Screening,” Nature Medicine 31 (2025): 917–924.

[141] R. J. Chen, M. Y. Lu, J. Wang, et al., “Pathomic Fusion: An Integrated Framework for Fusing Histopathology and Genomic Features for Cancer Diagnosis and Prognosis,” IEEE Transactions on Medical Imaging 41 (2022): 757–770.

[142] A. Cozzi, K. Pinker, A. Hidber, et al., “BI-RADS Category Assignments by GPT-3.5, GPT-4, and Google Bard: A Multilanguage Study,” Radiology 311 (2024): e232133.

[143] F. Liu, H. Zhou, B. Gu, et al., “Application of Large Language Models in Medicine,” Nature Reviews Bioengineering 3 (2025): 445–464.

[144] H. L. Haver, E. B. Ambinder, M. Bahl, E. T. Oluyemi, J. Jeudy, and P. H. Yi, “Appropriateness of Breast Cancer Prevention and Screening Recommendations Provided by ChatGPT,” Radiology 307 (2023): e230424.

[145] H. Xu, M. Wang, D. Shi, et al., “When Multiple Instance Learning Meets Foundation Models: Advancing Histological Whole Slide Image Analysis,” Medical Image Analysis 101 (2025): 103456.

[146] Z. Yang, T. Wei, Y. Liang, et al., “A Foundation Model for Generalizable Cancer Diagnosis and Survival Prediction From Histopathological Images,” Nature Communications 16 (2025): 2366.

[147] W. Zhao, Z. Guo, Y. Fan, Y. Jiang, M. C. F. Yeung, and L. Yu, “Aligning Knowledge Concepts to Whole Slide Images for Precise Histopathology Image Analysis,” NPJ Digital Medicine 7 (2024): 383.

[148] B. Kang, R. Fan, C. Cui, and Q. Cui, “Comprehensive Prediction and Analysis of human Protein Essentiality Based on a Pretrained Large Language Model,” Nature Computational Science 5 (2025): 196–206.

[149] H. Ding, W. Xia, Y. Zhou, et al., “Evaluation and Practical Application of Prompt-driven ChatGPTs for EMR Generation,” NPJ Digital Medicine 8 (2025): 77.

[150] M. Karimzadeh, A. Momen-Roknabadi, T. B. Cavazos, et al., “Deep Generative AI Models Analyzing Circulating Orphan Non-coding RNAs Enable Detection of Early-stage Lung Cancer,” Nature Communications 15 (2024): 10090.

[151] J. Huang, D. M. Yang, R. Rong, et al., “A Critical Assessment of Using ChatGPT for Extracting Structured Data From Clinical Notes,” NPJ Digital Medicine 7 (2024): 106.

[152] M. A. Fink, A. Bischoff, C. A. Fink, et al., “Potential of ChatGPT and GPT-4 for Data Mining of Free-Text CT Reports on Lung Cancer,” Radiology 308 (2023): e231362.

[153] S. Pai, D. Bontempi, I. Hadzic, et al., “Foundation Model for Cancer Imaging Biomarkers,” Nature Machine Intelligence 6 (2024): 354–367.

[154] M. Benary, X. D. Wang, M. Schmidt, et al., “Leveraging Large Language Models for Decision Support in Personalized Oncology,” JAMA Network Open 6 (2023): e2343689.

[155] A. A. Rahsepar, N. Tavakoli, G. H. J. Kim, C. Hassani, F. Abtin, and A. Bedayat, “How AI Responds to Common Lung Cancer Questions: ChatGPT vs Google Bard,” Radiology 307 (2023): e230922.

[156] A. A. Abreu, G. Z. Murimwa, E. Farah, et al., “Enhancing Readability of Online Patient-Facing Content: The Role of AI Chatbots in Improving Cancer Information Accessibility,” Journal of the National Comprehensive Cancer Network: JNCCN 22, no. 2 D (2024): e237334.

[157] S. Chen, M. Guevara, S. Moningi, et al., “The Effect of Using a Large Language Model to Respond to Patient Messages,” The Lancet Digital Health 6 (2024): e379–e381.

[158] D. Musheyev, A. Pan, P. Gross, et al., “Readability and Information Quality in Cancer Information from a Free vs Paid Chatbot,” JAMA Network Open 7 (2024): e2422275.

[159] S. Camacho, “A Needed Evolution to Improve Colorectal Cancer Screening: Binding Patient-centered/Shared Decision-making Medicine With Large Language Models in an Emerging Knowledge Society,” Endoscopy 57 (2025): 269–271.

[160] M. Maida, D. Ramai, Y. Mori, M. Dinis-Ribeiro, A. Facciorusso, and C. Hassan, “The Role of Generative Language Systems in Increasing Patient Awareness of Colon Cancer Screening,” Endoscopy 57 (2025): 262–268.

[161] Y. H. Yeo, J. S. Samaan, W. H. Ng, et al., “Assessing the Performance of ChatGPT in Answering Questions Regarding Cirrhosis and Hepatocellular Carcinoma,” Clinical and Molecular Hepatology 29 (2023): 721–732.

[162] P. W. Chang, M. M. Amini, R. O. Davis, et al., “ChatGPT4 Outperforms Endoscopists for Determination of Postcolonoscopy Rescreening and Surveillance Recommendations,” Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 22 (2024): 1917–1925.e1917.

[163] X. Wang, Y. Jiang, S. Yang, et al., “Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit from Digital Pathology in GI Cancers,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 43 (2025): 3468–3481.

[164] M. M. H. Fung, E. H. M. Tang, T. Wu, et al., “Developing a Named Entity Framework for Thyroid Cancer Staging and Risk Level Classification Using Large Language Models,” NPJ Digital Medicine 8 (2025): 134.

[165] B. Liang, Y. Gao, T. Wang, L. Zhang, and Q. Wang, “Multimodal Large Language Models Address Clinical Queries in Laryngeal Cancer Surgery: A Comparative Evaluation of Image Interpretation Across Different Models,” International Journal of Surgery (London, England) 111 (2025): 2727–2730.

[166] R. Bhayana, A. Jajodia, T. Chawla, et al., “Accuracy of Large Language Model-Based Automatic Calculation of Ovarian-Adnexal Reporting and Data System MRI Scores From Pelvic MRI Reports,” Radiology 315 (2025): e241554.

[167] J. M. Unger, R. Vaidya, D. L. Hershman, L. M. Minasian, and M. E. Fleury, “Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation,” Journal of the National Cancer Institute 111 (2019): 245–255.

[168] D. Elliott, S. Husbands, F. C. Hamdy, L. Holmberg, and J. L. Donovan, “Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches,” European Urology 72 (2017): 789–798.

[169] N. P. Verdini, K. L. Bryl, R. E. Baser, K. Lapen, J. J. Mao, and E. F. Gillespie, “Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment,” JAMA Oncology 10 (2024): 784–788.

[170] E. A. Largent and H. F. Lynch, “Addressing Financial Barriers to Enrollment in Clinical Trials,” JAMA Oncology 4 (2018): 913–914.

[171] O. Unlu, M. Varugheese, J. Shin, et al., “Manual vs AI-Assisted Prescreening for Trial Eligibility Using Large Language Models-A Randomized Clinical Trial,” Jama 333 (2025): 1084–1087.

[172] Y. Hswen and N. Collins, “Study Finds AI Can Quickly Prescreen Patients for Clinical Trials, Speeding Enrollment,” Jama 333 (2025): 1275–1277.

[173] K. Zhang, X. Yang, Y. Wang, et al., “Artificial Intelligence in Drug Development,” Nature Medicine 31 (2025): 45–59.

[174] J. E. Liddicoat, G. Lenarczyk, M. Aboy, T. Minssen, and S. P. Mann, “A Policy Framework for Leveraging Generative AI to Address Enduring Challenges in Clinical Trials,” NPJ Digital Medicine 8 (2025): 33.

[175] Z. Kraljevic, D. Bean, A. Shek, et al., “Foresight-a Generative Pretrained Transformer for Modelling of Patient Timelines Using Electronic Health Records: A Retrospective Modelling Study,” The Lancet Digital Health 6 (2024): e281–e290.

[176] Q. Jin, Z. Wang, C. S. Floudas, et al., “Matching Patients to Clinical Trials With Large Language Models,” Nature Communications 15 (2024): 9074.

[177] S. Gupta, A. Basu, M. Nievas, et al., “PRISM: Patient Records Interpretation for Semantic Clinical Trial Matching System Using Large Language Models,” NPJ Digital Medicine 7 (2024): 305.

[178] R. Y. Lee, E. K. Kross, J. Torrence, et al., “Assessment of Natural Language Processing of Electronic Health Records to Measure Goals-of-Care Discussions as a Clinical Trial Outcome,” JAMA Network Open 6 (2023): e231204.

[179] D. D. Reiff, M. L. Stoll, and R. Q. Cron, “Precision Medicine in Juvenile Idiopathic Arthritis-has the Time Arrived?,” The Lancet Rheumatology 3 (2021): e808–e817.

[180] S. Harrer, P. Shah, B. Antony, and J. Hu, “Artificial Intelligence for Clinical Trial Design,” Trends in Pharmacological Sciences 40 (2019): 577–591.

[181] M. Hutson, “How AI Is Being Used to Accelerate Clinical Trials,” Nature 627 (2024): S2–s5.

[182] M. S. von Itzstein, M. Hullings, H. Mayo, M. S. Beg, E. L. Williams, and D. E. Gerber, “Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review,” JAMA Oncology 7 (2021): 1559–1566.

[183] K. M. Boehm, P. Khosravi, R. Vanguri, J. Gao, and S. P. Shah, “Harnessing Multimodal Data Integration to Advance Precision Oncology,” Nature Reviews Cancer 22 (2022): 114–126.

[184] R. Lin, Z. Zhao, Z. Liu, et al., “Artificial Intelligence in Clinical Oncology: Multimodal Integration and Translational Development,” Cancer Letters 649 (2026): 218493.

[185] M. Y. Lu, B. Chen, D. F. K. Williamson, et al., “A Multimodal Generative AI Copilot for human Pathology,” Nature 634 (2024): 466–473.

[186] Y. Zheng, B. Qiu, S. Liu, et al., “A Transformer-Based Deep Learning Model for Early Prediction of Lymph Node Metastasis in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Using Pretreatment CT Images,” EClinicalMedicine 75 (2024): 102805.

[187] K. M. Boehm, O. S. M. El Nahhas, A. Marra, et al., “Multimodal Histopathologic Models Stratify Hormone Receptor-positive Early Breast Cancer,” Nature Communications 16 (2025): 2106.

[188] J. M. Josephides and C. L. Chen, “Unravelling Single-cell DNA Replication Timing Dynamics Using Machine Learning Reveals Heterogeneity in Cancer Progression,” Nature Communications 16 (2025): 1472.

[189] G. Jia, P. He, T. Dai, et al., “Spatial Immune Scoring System Predicts Hepatocellular Carcinoma Recurrence,” Nature 640 (2025): 1031–1041.

[190] A. Osipov, O. Nikolic, A. Gertych, et al., “The Molecular Twin Artificial-intelligence Platform Integrates Multi-omic Data to Predict Outcomes for Pancreatic Adenocarcinoma Patients,” Nature Cancer 5 (2024): 299–314.

[191] Y. Z. Jiang, D. Ma, X. Jin, et al., “Integrated Multiomic Profiling of Breast Cancer in the Chinese Population Reveals Patient Stratification and Therapeutic Vulnerabilities,” Nature Cancer 5 (2024): 673–690.

[192] M. Hao, J. Gong, X. Zeng, et al., “Large-Scale Foundation Model on Single-cell Transcriptomics,” Nature Methods 21 (2024): 1481–1491.

[193] M. Hu, S. Alkhairy, I. Lee, et al., “Evaluation of Large Language Models for Discovery of Gene Set Function,” Nature Methods 22 (2025): 82–91.

[194] H. Li, Z. Han, Y. Sun, et al., “CGMega: Explainable Graph Neural Network Framework With Attention Mechanisms for Cancer Gene Module Dissection,” Nature Communications 15 (2024): 5997.

[195] T. Shen, Z. Hu, S. Sun, et al., “Accurate RNA 3D Structure Prediction Using a Language Model-Based Deep Learning Approach,” Nature Methods 21 (2024): 2287–2298.

[196] R. Chowdhury, N. Bouatta, S. Biswas, et al., “Single-sequence Protein Structure Prediction Using a Language Model and Deep Learning,” Nature Biotechnology 40 (2022): 1617–1623.

[197] C. Swanton, E. Bernard, C. Abbosh, et al., “Embracing Cancer Complexity: Hallmarks of Systemic Disease,” Cell 187 (2024): 1589–1616.

[198] H. Ma, S. Srivastava, S. W. T. Ho, et al., “Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution,” Cancer Discovery 15 (2025): 767–792.

[199] K. Jin, T. Yu, G. S. Ying, et al., “A Systematic Review of Vision and Vision-language Foundation Models in Ophthalmology,” Advances in Ophthalmology Practice and Research 6 (2026): 8–19.

[200] T. Han, S. Nebelung, F. Khader, et al., “Medical Large Language Models Are Susceptible to Targeted Misinformation Attacks,” NPJ Digital Medicine 7 (2024): 288.

[201] D. A. Alber, Z. Yang, A. Alyakin, et al., “Medical Large Language Models Are Vulnerable to Data-poisoning Attacks,” Nature Medicine 31 (2025): 618–626.

[202] S. Farquhar, J. Kossen, L. Kuhn, and Y. Gal, “Detecting Hallucinations in Large Language Models Using Semantic Entropy,” Nature 630 (2024): 625–630.

[203] S. Gilbert, J. N. Kather, and A. Hogan, “Augmented Non-hallucinating Large Language Models as Medical Information Curators,” NPJ Digital Medicine 7 (2024): 100.

[204] I. C. Wiest, M.-E. Leßmann, F. Wolf, et al., “Deidentifying Medical Documents With Local,” Privacy-Preserving Large Language Models: The LLM-Anonymizer 2 (2025): AIdbp2400537.

[205] J. C. L. Ong, S. Y. Chang, W. William, et al., “Ethical and Regulatory Challenges of Large Language Models in Medicine,” The Lancet Digital Health 6 (2024): e428–e432.

[206] T. Ifargan, L. Hafner, M. Kern, O. Alcalay, and R. Kishony, Autonomous LLM-Driven Research — from Data to Human-Verifiable Research Papers 2 (2025): AIoa2400555.

[207] M. Steyvers, H. Tejeda, A. Kumar, et al., “What Large Language Models Know and What People Think They Know,” Nature Machine Intelligence 7 (2025): 221–231.

[208] J. Feng, F. Xia, K. Singh, and R. Pirracchio, “Not All Clinical AI Monitoring Systems Are Created Equal: Review and Recommendations,” 2 (2025): AIra2400657.

[209] G. E. Weissman, T. Mankowitz, and G. P. Kanter, “Unregulated Large Language Models Produce Medical Device-Like Output,” NPJ Digital Medicine 8 (2025): 148.

[210] O. Freyer, I. C. Wiest, J. N. Kather, and S. Gilbert, “A Future Role for Health Applications of Large Language Models Depends on Regulators Enforcing Safety Standards,” The Lancet Digital Health 6 (2024): e662–e672.

[211] J. Schmidt, N. M. Schutte, S. Buttigieg, et al., “Mapping the Regulatory Landscape for Artificial Intelligence in Health Within the European Union,” NPJ Digital Medicine 7 (2024): 229.

[212] Y. Han, A. Ceross, and J. Bergmann, “Regulatory Frameworks for AI-Enabled Medical Device Software in China: Comparative Analysis and Review of Implications for Global Manufacturer,” JMIR AI 3 (2024): e46871.

[213] S. Gilbert, H. Harvey, T. Melvin, E. Vollebregt, and P. Wicks, “Large Language Model AI Chatbots Require Approval as Medical Devices,” Nature Medicine 29 (2023): 2396–2398.

[214] H. J. Warraich, T. Tazbaz, and R. M. Califf, “FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine,” Jama 333 (2025): 241–247.

[215] A. D. Saenz, Z. Harned, O. Banerjee, M. D. Abràmoff, and P. Rajpurkar, “Autonomous AI Systems in the Face of Liability, Regulations and Costs,” NPJ Digital Medicine 6 (2023): 185.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.